Public Health Impact of Paxlovid as Treatment for COVID-19, United States
We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03-0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62-$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36-1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49-$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 30(2024), 2 vom: 13. Feb., Seite 262-269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bai, Yuan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 02.02.2024 published: Print-Electronic UpdateOf: medRxiv. 2023 Sep 07;:. - PMID 37732213 Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid3002.230835 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366724150 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366724150 | ||
| 003 | DE-627 | ||
| 005 | 20240202232127.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid3002.230835 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM366724150 | ||
| 035 | |a (NLM)38181800 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bai, Yuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Public Health Impact of Paxlovid as Treatment for COVID-19, United States |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2023 Sep 07;:. - PMID 37732213 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03-0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62-$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36-1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49-$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Paxlovid | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2 transmission | |
| 650 | 4 | |a United States | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a mathematical model | |
| 650 | 4 | |a public health impact | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a zoonoses | |
| 650 | 7 | |a nirmatrelvir and ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a Lactams |2 NLM | |
| 700 | 1 | |a Du, Zhanwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Eric H Y |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Isaac Chun-Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Holme, Petter |e verfasserin |4 aut | |
| 700 | 1 | |a Cowling, Benjamin J |e verfasserin |4 aut | |
| 700 | 1 | |a Galvani, Alison P |e verfasserin |4 aut | |
| 700 | 1 | |a Krug, Robert M |e verfasserin |4 aut | |
| 700 | 1 | |a Meyers, Lauren Ancel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 30(2024), 2 vom: 13. Feb., Seite 262-269 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g day:13 |g month:02 |g pages:262-269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid3002.230835 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |b 13 |c 02 |h 262-269 | ||